Loading...
Researchers have suggested that concomitant use of clopidogrel and proton-pump inhibitors (PPIs) is associated with elevated risk for cardiovascular disease (CVD) events. In this retrospective cohort study, investigators reviewed Tennessee Medicaid data for 20,596 patients who received clopidogrel after hospitalization for myocardial infarctions (MIs), coronary artery revascularization, or unstable angina during a 7-year period; 37% received concomitant PPI therapy.
PPI recipients experienced fewer hospitalizations for gastrointestinal bleeding than did nonrecipients (8.2 vs. 12.2 per 1000 person-years). Results remained significant (hazard ratio, 0.50) in analyses adjusted for demographics, other medication use, diagnosis and procedures, an…